{"id":44790,"date":"2022-06-07T14:01:27","date_gmt":"2022-06-07T12:01:27","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/code-biotherapeutics-raises-upsized-and-oversubscribed-75-million-in-series-a-financing-to-develop-therapies-for-debilitating-genetic-diseases\/"},"modified":"2022-06-07T14:01:27","modified_gmt":"2022-06-07T12:01:27","slug":"code-biotherapeutics-raises-upsized-and-oversubscribed-75-million-in-series-a-financing-to-develop-therapies-for-debilitating-genetic-diseases","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/code-biotherapeutics-raises-upsized-and-oversubscribed-75-million-in-series-a-financing-to-develop-therapies-for-debilitating-genetic-diseases\/","title":{"rendered":"Code Biotherapeutics Raises Upsized and Oversubscribed $75 Million in Series A Financing to Develop Therapies for Debilitating Genetic Diseases"},"content":{"rendered":"
\n

\n– Round led by Northpond Ventures with participation from new investors Amgen Ventures, Hatteras Venture Partners and UCB Ventures alongside existing investors<\/i>\n<\/p>\n

<\/a><\/p>\n

\n– Proceeds will enable Code Bio to advance its lead programs in Duchenne Muscular Dystrophy (DMD) and type 1 diabetes (T1D) towards IND-enabling studies, expand its pipeline and platform applications, and further scale manufacturing and operations<\/i>\n<\/p>\n

GREATER PHILADELPHIA, Pa.–(BUSINESS WIRE)–Code Biotherapeutics<\/a>, Inc. (Code Bio), a biotechnology company pioneering targeted non-viral delivery of genetic medicines, today announced its upsized and oversubscribed Series A financing of $75 million to advance programs to treat and cure rare and prevalent genetic diseases. Northpond Ventures led the financing round with participation from Amgen Ventures, Hatteras Venture Partners and UCB Ventures alongside existing investors New Enterprise Associates, 4BIO Capital, CureDuchenne Ventures, the JDRF T1D Fund, UPMC Enterprises, and Takeda Ventures. The funding enables the company to advance its two lead programs in DMD and T1D toward IND-enabling studies, expand its pipeline and platform applications, and expand its manufacturing and operations.\n<\/p>\n

\n\u201cPatients with rare and prevalent genetic diseases, and their caregivers, are in need of breakthrough treatments that will truly make a difference in their lives,\u201d said Brian P. McVeigh, Code Bio Co-Founder, Chairman, and Chief Executive Officer. \u201cWe\u2019re energized by the confidence these high-caliber, top-tier investors are demonstrating through their support as we drive our discovery programs forward and strive to rapidly deliver on the promise our proprietary synthetic DNA-based, non-viral genetic medicines delivery platform holds.\u201d\n<\/p>\n

\nCode Bio\u2019s 3DNA\u00ae platform has demonstrated the potential to deliver various genetic medicines to multiple cell types in a tissue-targeted, re-dosable manner, which enables its use across a broad range of genetic disorders. The 3DNA\u00ae platform is designed to fully unlock the potential of genetic medicines and overcome key limitations of other delivery approaches.\n<\/p>\n

\nAs part of the financing, Diana Bernstein, Ph.D., Vice President at Northpond Ventures, will join Code Bio\u2019s board of directors.\n<\/p>\n

\n\u201cCode Bio\u2019s targeted 3DNA\u00ae delivery platform is positioned to extend the utility of genetic medicines beyond what\u2019s currently possible with viral gene delivery in support of the development of transformative therapies,\u201d said Dr. Bernstein. \u201cThe potential of this technology aligns with our purpose as a science-driven venture capital firm with a mission of supporting innovations that hold promise for patients suffering from serious and life-threatening diseases.\u201d\n<\/p>\n

\n\u201cWe are impressed with the progress that the Code Bio team has made since the initial seed financing round only a year ago,\u201d said Ed Mathers, General Partner, New Enterprise Associates. \u201cNEA is pleased to remain a strong supporter as the company advances its discovery programs to treat and cure rare and prevalent genetic diseases and leverages the value of its innovative 3DNA\u00ae platform.\u201d\n<\/p>\n

\nAbout Code Biotherapeutics, Inc.<\/b>\n<\/p>\n

\nHeadquartered in Greater Philadelphia, Code Bio is a biotechnology company <\/b>pioneering the development of genetic medicines to treat and potentially cure serious and life-threatening genetic diseases. By leveraging its novel non-viral multivalent synthetic DNA delivery platform, 3DNA\u00ae, Code Bio\u2019s approach can overcome multiple challenges inherent with viral-based delivery approaches, including immunogenicity, size and delivery limitations, inability to re-dose and manufacturing complexity. The company is advancing an internal pipeline of therapies focused on serious and life-threatening diseases while also developing multiple collaborative partnerships to take forward additional programs in both rare and prevalent diseases. For more information, visit www.codebiotx.com<\/a>.\n<\/p>\n

\nAbout Northpond Ventures<\/b>\n<\/p>\n

\nNorthpond Ventures is a multi-billion-dollar science-driven venture capital firm based in Cambridge, MA; San Francisco, CA; and Bethesda, MD. Northpond has been named one of the three most active lead biotech investors in 2021 by Crunchbase, and the most active lead investor in life science solutions and molecular diagnostics by Silicon Valley Bank. It is particularly engaged in the research ecosystem, having led over 50 financings over the past several years, a high percentage of which have an academic origin. Learn more at npv.vc<\/a>.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nCode Bio Media:<\/b>
Mike Beyer
\n
Sam Brown Inc. Healthcare Communications
\n
312-961-2502
\n
mikebeyer@sambrown.com<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

– Round led by Northpond Ventures with participation from new investors Amgen Ventures, Hatteras Venture Partners and UCB Ventures alongside existing investors – Proceeds will enable Code Bio to advance its lead programs in Duchenne Muscular Dystrophy (DMD) and type 1 diabetes (T1D) towards IND-enabling studies, expand its pipeline and platform applications, and further scale … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-44790","6":"format-standard","7":"category-industry"},"yoast_head":"\nCode Biotherapeutics Raises Upsized and Oversubscribed $75 Million in Series A Financing to Develop Therapies for Debilitating Genetic Diseases - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/code-biotherapeutics-raises-upsized-and-oversubscribed-75-million-in-series-a-financing-to-develop-therapies-for-debilitating-genetic-diseases\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Code Biotherapeutics Raises Upsized and Oversubscribed $75 Million in Series A Financing to Develop Therapies for Debilitating Genetic Diseases - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"– Round led by Northpond Ventures with participation from new investors Amgen Ventures, Hatteras Venture Partners and UCB Ventures alongside existing investors – Proceeds will enable Code Bio to advance its lead programs in Duchenne Muscular Dystrophy (DMD) and type 1 diabetes (T1D) towards IND-enabling studies, expand its pipeline and platform applications, and further scale ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/code-biotherapeutics-raises-upsized-and-oversubscribed-75-million-in-series-a-financing-to-develop-therapies-for-debilitating-genetic-diseases\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-06-07T12:01:27+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20220607005030\/en\/1078761\/21\/CodeBio_Logo.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/code-biotherapeutics-raises-upsized-and-oversubscribed-75-million-in-series-a-financing-to-develop-therapies-for-debilitating-genetic-diseases\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/code-biotherapeutics-raises-upsized-and-oversubscribed-75-million-in-series-a-financing-to-develop-therapies-for-debilitating-genetic-diseases\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Code Biotherapeutics Raises Upsized and Oversubscribed $75 Million in Series A Financing to Develop Therapies for Debilitating Genetic Diseases\",\"datePublished\":\"2022-06-07T12:01:27+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/code-biotherapeutics-raises-upsized-and-oversubscribed-75-million-in-series-a-financing-to-develop-therapies-for-debilitating-genetic-diseases\\\/\"},\"wordCount\":681,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/code-biotherapeutics-raises-upsized-and-oversubscribed-75-million-in-series-a-financing-to-develop-therapies-for-debilitating-genetic-diseases\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220607005030\\\/en\\\/1078761\\\/21\\\/CodeBio_Logo.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/code-biotherapeutics-raises-upsized-and-oversubscribed-75-million-in-series-a-financing-to-develop-therapies-for-debilitating-genetic-diseases\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/code-biotherapeutics-raises-upsized-and-oversubscribed-75-million-in-series-a-financing-to-develop-therapies-for-debilitating-genetic-diseases\\\/\",\"name\":\"Code Biotherapeutics Raises Upsized and Oversubscribed $75 Million in Series A Financing to Develop Therapies for Debilitating Genetic Diseases - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/code-biotherapeutics-raises-upsized-and-oversubscribed-75-million-in-series-a-financing-to-develop-therapies-for-debilitating-genetic-diseases\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/code-biotherapeutics-raises-upsized-and-oversubscribed-75-million-in-series-a-financing-to-develop-therapies-for-debilitating-genetic-diseases\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220607005030\\\/en\\\/1078761\\\/21\\\/CodeBio_Logo.jpg\",\"datePublished\":\"2022-06-07T12:01:27+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/code-biotherapeutics-raises-upsized-and-oversubscribed-75-million-in-series-a-financing-to-develop-therapies-for-debilitating-genetic-diseases\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/code-biotherapeutics-raises-upsized-and-oversubscribed-75-million-in-series-a-financing-to-develop-therapies-for-debilitating-genetic-diseases\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/code-biotherapeutics-raises-upsized-and-oversubscribed-75-million-in-series-a-financing-to-develop-therapies-for-debilitating-genetic-diseases\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220607005030\\\/en\\\/1078761\\\/21\\\/CodeBio_Logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220607005030\\\/en\\\/1078761\\\/21\\\/CodeBio_Logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/code-biotherapeutics-raises-upsized-and-oversubscribed-75-million-in-series-a-financing-to-develop-therapies-for-debilitating-genetic-diseases\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Code Biotherapeutics Raises Upsized and Oversubscribed $75 Million in Series A Financing to Develop Therapies for Debilitating Genetic Diseases\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Code Biotherapeutics Raises Upsized and Oversubscribed $75 Million in Series A Financing to Develop Therapies for Debilitating Genetic Diseases - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/code-biotherapeutics-raises-upsized-and-oversubscribed-75-million-in-series-a-financing-to-develop-therapies-for-debilitating-genetic-diseases\/","og_locale":"en_US","og_type":"article","og_title":"Code Biotherapeutics Raises Upsized and Oversubscribed $75 Million in Series A Financing to Develop Therapies for Debilitating Genetic Diseases - Pharma Trend","og_description":"– Round led by Northpond Ventures with participation from new investors Amgen Ventures, Hatteras Venture Partners and UCB Ventures alongside existing investors – Proceeds will enable Code Bio to advance its lead programs in Duchenne Muscular Dystrophy (DMD) and type 1 diabetes (T1D) towards IND-enabling studies, expand its pipeline and platform applications, and further scale ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/code-biotherapeutics-raises-upsized-and-oversubscribed-75-million-in-series-a-financing-to-develop-therapies-for-debilitating-genetic-diseases\/","og_site_name":"Pharma Trend","article_published_time":"2022-06-07T12:01:27+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20220607005030\/en\/1078761\/21\/CodeBio_Logo.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/code-biotherapeutics-raises-upsized-and-oversubscribed-75-million-in-series-a-financing-to-develop-therapies-for-debilitating-genetic-diseases\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/code-biotherapeutics-raises-upsized-and-oversubscribed-75-million-in-series-a-financing-to-develop-therapies-for-debilitating-genetic-diseases\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Code Biotherapeutics Raises Upsized and Oversubscribed $75 Million in Series A Financing to Develop Therapies for Debilitating Genetic Diseases","datePublished":"2022-06-07T12:01:27+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/code-biotherapeutics-raises-upsized-and-oversubscribed-75-million-in-series-a-financing-to-develop-therapies-for-debilitating-genetic-diseases\/"},"wordCount":681,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/code-biotherapeutics-raises-upsized-and-oversubscribed-75-million-in-series-a-financing-to-develop-therapies-for-debilitating-genetic-diseases\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220607005030\/en\/1078761\/21\/CodeBio_Logo.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/code-biotherapeutics-raises-upsized-and-oversubscribed-75-million-in-series-a-financing-to-develop-therapies-for-debilitating-genetic-diseases\/","url":"https:\/\/pharma-trend.com\/en\/code-biotherapeutics-raises-upsized-and-oversubscribed-75-million-in-series-a-financing-to-develop-therapies-for-debilitating-genetic-diseases\/","name":"Code Biotherapeutics Raises Upsized and Oversubscribed $75 Million in Series A Financing to Develop Therapies for Debilitating Genetic Diseases - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/code-biotherapeutics-raises-upsized-and-oversubscribed-75-million-in-series-a-financing-to-develop-therapies-for-debilitating-genetic-diseases\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/code-biotherapeutics-raises-upsized-and-oversubscribed-75-million-in-series-a-financing-to-develop-therapies-for-debilitating-genetic-diseases\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220607005030\/en\/1078761\/21\/CodeBio_Logo.jpg","datePublished":"2022-06-07T12:01:27+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/code-biotherapeutics-raises-upsized-and-oversubscribed-75-million-in-series-a-financing-to-develop-therapies-for-debilitating-genetic-diseases\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/code-biotherapeutics-raises-upsized-and-oversubscribed-75-million-in-series-a-financing-to-develop-therapies-for-debilitating-genetic-diseases\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/code-biotherapeutics-raises-upsized-and-oversubscribed-75-million-in-series-a-financing-to-develop-therapies-for-debilitating-genetic-diseases\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20220607005030\/en\/1078761\/21\/CodeBio_Logo.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20220607005030\/en\/1078761\/21\/CodeBio_Logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/code-biotherapeutics-raises-upsized-and-oversubscribed-75-million-in-series-a-financing-to-develop-therapies-for-debilitating-genetic-diseases\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Code Biotherapeutics Raises Upsized and Oversubscribed $75 Million in Series A Financing to Develop Therapies for Debilitating Genetic Diseases"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/44790","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=44790"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/44790\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=44790"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=44790"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=44790"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}